Komal Jhaveri, MD, FACP, FASCO is an associate attending physician within the Breast Medicine and Early Drug Development Services at Memorial Sloan Kettering Cancer Center in New York. She serves as the section head for the Endocrine Therapy Research Program within the Breast Medicine Service.  She is the recipient of the Patricia and James Cayne Chair for junior faculty. She is also an associate professor in the department of medicine at Weill Cornell Medicine.

 

She earned her medical degree followed by a training in nuclear medicine from the University of Mumbai. She later completed her Internal Medicine residency from Icahn School of Medicine at Mount Sinai (Morningside/West) Program in New York and her Medical Oncology/ Hematology fellowship at MSKCC. From July 2012-May 2015, she served as an Assistant Professor in the DOM at New York University and as an Attending Physician at the Langone Medical Center and at Bellevue Hospital.

 

Her research focuses on the development of improved therapies for patients with breast cancer by conducting novel clinical trials integrated with translational biomarker work through acquired biospecimen (cfDNA and tumor) or imaging analyses. She’s led the development of PI3K/Akt inhibitors, FGFR inhibitors, ERBB2 inhibitors, novel endocrine agents, and antibody-drug conjugates, among others. She serves as a member of the ASCO/TAPUR Molecular Tumor Board and is the Co-Chair for the Endocrine Resistance working group within the Translational Breast Cancer Research Consortium. Her work has been presented at annual scientific meetings of ASCO, AACR, ESMO, SABCS and has been published widely in many reputable journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology among others. 

Dr Komal Jhaveri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant/advisory board role: Novartis, Pfizer, Genentech, Eisai, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Menarini/Stemline, Gilead, Scorpion Therapeutics, Bicycle Therapeutics, Olema Pharmaceuticals, Lilly/Loxo Oncology, Merck Pharmaceuticals, Zymeworks, Halda Therapeutics, Arivinas and Rayzebio

 

Research Funding support to the Institution: Novartis, Genentech, AstraZeneca, Pfizer, Lilly/Loxo Oncology, Zymeworks, Gilead, PUMA Biotechnology, Merck Pharmaceuticals, Scorpion Therapeutics, Rayzebio, Eisai and Blueprint Medicines.